NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial for Preclinical Alzheimer's Disease

A genotype-stratified, biomarker-driven enrollment strategy places NewAmsterdam Pharma's SPINOZA trial at the intersection of precision medicine design and evolving FDA expectations for early-phase CNS studies, with direct implications for CMC teams managing small-molecule supply for molecularly defined patient populations. The company dosed the first participant on 29 September 2026 in this Phase 2b evaluation of obicetrapib in preclinical Alzheimer's disease.

SPINOZA is a randomized, double-blind, placebo-controlled, parallel-group study targeting approximately 400 adults who carry biomarker evidence consistent with early Alzheimer's pathology but present no noticeable memory or functional symptoms. Eligible participants carry ApoE4/E4, ApoE3/E4, or ApoE3/E3 genotypes and will be randomized 1:1, stratified by genotype, to receive obicetrapib 10 mg or placebo over 52 weeks. A 26-week open-label extension follows, during which all participants receive active treatment.

The trial design was informed by a prespecified Alzheimer's disease biomarker analysis from the Phase 3 BROADWAY trial, which identified the strongest biomarker response in ApoE4/E4 participants and supportive signals across additional genotype-defined populations. Primary endpoints include changes in blood-based biomarkers associated with Alzheimer's pathology, notably p-tau 217, alongside cognitive and functional measures. For regulatory affairs leads, the genotype-stratified randomization and biomarker-defined enrollment reflect the kind of precision medicine trial architecture that agencies have signaled preference for in recent draft guidance on early Alzheimer's intervention studies.

From a manufacturing and CMC standpoint, genotype-stratified enrollment introduces supply-planning complexity that standard Phase 2b models do not. Enrollment velocity will depend on biomarker screening throughput and genotype prevalence in the recruited population, making demand forecasting for obicetrapib 10 mg tablets less linear than a broad-inclusion design. QA and supply chain leads supporting the trial should account for potential enrollment variability when setting batch release schedules and expiry management protocols.

Obicetrapib is a novel oral CETP inhibitor with an established Phase 2 and Phase 3 dataset across cardiovascular indications, including the ongoing REMBRANDT, RUBENS, and PREVAIL trials. The scientific rationale for the Alzheimer's extension rests on the link between lipid metabolism and neurodegeneration, with the BROADWAY biomarker analysis providing the primary evidentiary basis for SPINOZA's design.

Enrollment completion and interim biomarker readouts from SPINOZA will serve as the first measurable test of whether obicetrapib's lipid-modulating mechanism translates to a detectable effect on p-tau 217 trajectories in a genotype-stratified preclinical population.

Source: NewAmsterdam Pharma via GlobeNewswire, 29 September 2026.